Dorsey Wright & Associates’s Bio-Rad Laboratories Class A BIO Stock Holding History

Dorsey Wright & Associates’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,410	Closed	-$2.58M	–	289
2021 Q4	$2.58M	Buy	+3,410	New	+$2.55M	0.53%	90
2019 Q1	–	Sell	-6,620	Closed	-$1.54M	–	293
2018 Q4	$1.54M	Sell	6,620 -16,872	-72%	-$4.53M	0.46%	86
2018 Q3	$7.35M	Buy	23,492 +15,059	+179%	+$4.67M	1.34%	20
2018 Q2	$2.43M	Buy	8,433 +78	+0.9%	+$21.5K	0.36%	81
2018 Q1	$2.09M	Buy	8,355 +86	+1%	+$21.9K	0.32%	83
2017 Q4	$1.97M	Sell	8,269 -7,514	-48%	-$1.82M	0.36%	88
2017 Q3	$3.51M	Buy	15,783 +7,834	+99%	+$1.76M	0.81%	63
2017 Q2	$1.8M	Buy	+7,949	New	+$1.73M	0.55%	81

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dorsey Wright & Associates's BIO Position: Q1 2022 in Review

Dorsey Wright & Associates sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2022, closing a stake of 3,410 shares — an estimated $2.58M sold.

Dorsey Wright & Associates first reported a position in BIO in Q2 2017 and held it in 8 quarters. The position peaked at $7.35M in Q3 2018. 514 funds tracked by Wall St. Rank hold BIO as of Q1 2022.

Dorsey Wright & Associates reported no remaining Bio-Rad Laboratories Class A position as of Q1 2022 after selling out during the quarter.
Dorsey Wright & Associates sold 3,410 Bio-Rad Laboratories Class A shares in Q1 2022, an estimated $2.58M.
Dorsey Wright & Associates first reported a position in Bio-Rad Laboratories Class A in Q2 2017 and held it in 8 quarters.
Dorsey Wright & Associates's Bio-Rad Laboratories Class A position peaked at $7.35M in Q3 2018.
514 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2022.

Based on Dorsey Wright & Associates's 13F filing for Q1 2022, filed 27 Apr 2022.